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Abstract
Background: Hypoxia-ischemia (H-I) can produce widespread neurodegeneration and deep cerebral white matter
injury in the neonate. Resident microglia and invading leukocytes promote lesion progression by releasing reactive
oxygen species, proteases and other pro-inflammatory mediators. After injury, expression of the gelatin-degrading matrix
metalloproteinases (MMPs), MMP-2 and MMP-9, are thought to result in the proteolysis of extracellular matrix (ECM),
activation of cytokines/chemokines, and the loss of vascular integrity. Thus, therapies targeting ECM degradation and
progressive neuroinflammation may be beneficial in reducing H-I – induced neuropathy. Minocycline has MMP-inhibitory
properties and is both anti-inflammatory and neuroprotective. AG3340 (prinomastat) is an MMP inhibitor with high
selectivity for the gelatinases. The purpose of this study was to determine whether these compounds could limit H-I –
induced injury when administered at a delayed time point.
Methods: Sprague-Dawley rats were exposed to H-I at postnatal day 7 (P7), consisting of unilateral carotid artery
ligation followed by 90 min exposure to 8% O2. Minocycline, AG3340, or vehicle were administered once daily for 6 days,
beginning 24 hours after insult. Animals were sacrificed at P14 for neurohistological assessments. Immunohistochemistry
was performed to determine the degree of reactive astrogliosis and immune cell activation/recruitment. Neural injury
was detected using the Fluoro-Jade stain, a marker that identifies degenerating cells.
Results: CD11b and glial fibrillary acidic protein (GFAP) immunopositive cells increased in ipsilateral cortex after
treatment with vehicle alone, demonstrating microglia/macrophage recruitment and reactive astrogliosis, respectively.
Fluoro-Jade staining was markedly increased throughout the fronto-parietal cortex, striatum and hippocampus.
Treatment with minocycline or AG3340 inhibited microglia/macrophage recruitment, attenuated astrogliosis and
reduced Fluoro-Jade staining when compared to vehicle alone.
Conclusion: The selective gelatinase inhibitor AG3340 showed equal efficacy in reducing neural injury and dampening
neuroinflammation when compared to the anti-inflammatory compound minocycline. Thus, MMP-2 and MMP-9 may be
viable therapeutic targets to treat neonatal brain injury.
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Background
Exposure to a hypoxic-ischemic (H-I) insult has distinc-
tive consequences in the developing brain. An immature
vasculature and low baseline blood flow render the neo-
natal brain susceptible to even modest changes in per-
fusion pressure [1]. The maladaptive neurobiological
response can be severe, resulting in deep cerebral white
matter injury and substantial neuronal loss [2]. Similar to
the human condition, neonatal rodent models recapitu-
lating these injuries show cortical and subcortical infarc-
tions, impaired motor function [3-5] and cognitive
deficits [6-8]. Previous studies have linked oxidative stress
[9,10] and NMDA receptor activation [11] to white matter
injury, while glutamatergic blockade has been shown to
reduce H-I-induced infarction [12-14] and white matter
damage [15]. Though excitotoxicity and free radical pro-
duction are key contributors to the neuropathology of
these lesions, there is a growing interest in identifying
additional therapies to limit the progressive neuroinflam-
mation that accompanies ischemic injury.
Inflammation occurs in response to injury and initiates
pathological responses that potentiate neural injury. The
release of proteases from activated glia results in proteo-
lytic degradation of basement membrane constituents.
This breakdown compromises the blood brain barrier,
likely allowing entry of peripheral neutrophils and macro-
phages into the brain. These cells, along with resident
microglia, secrete pro-inflammatory cytokines and chem-
okines that further enhance microglia/macrophage
recruitment to the injured site. Matrix metalloproteinases
(MMPs), the most well-studied extracellular matrix
(ECM)-degrading proteases, are capable of processing
TNF-α [16], IL-1β [17] and SDF-1α [18] to their biologi-
cally active forms. Several MMPs, particularly the gelati-
nases, are elevated after cerebral ischemia and have been
shown to degrade basement membrane proteins [19,20].
In culture, MMP-2 – positive astrocytes produced MMP-9
when stimulated with either TNF-α or IL-1β [21]. In vivo,
MMP-2 expression increased in astrocytic endfeet of rats
exposed to MCAO, while MMP-9 expression was localized
to neutrophils and endothelial cells [22]. Interestingly,
elevated gelatinolytic activity colocalized with neuronal
laminin degradation after focal ischemia, effects that were
attenuated after administration of a highly selective MMP
inhibitor [23]. In agreement with these data, mice lacking
MMP-9 showed improved outcomes that were directly
related to reduced microglial activation [24], attenuated
blood brain barrier degradation [25] and limited white
matter damage [26] after H-I.
In addition to cytokines and basement membrane pro-
teins, MMPs cleave ECM chondroitin sulfate proteogly-
cans (CSPGs). Proteolytic processing of ECM
proteoglycans has been linked to H-I pathology in the rat
neonate [27], and recent data showed altered proteogly-
can expression that was associated with progressive injury
[28]. While CSPGs are known substrates for several fami-
lies of matrix-degrading proteases [13,29,30], little is
known about the precise regulation of proteoglycan turn-
over after H-I.
Although neuropathological outcomes show improve-
ment in MMP null mice [24-26], the need for clinically
relevant therapeutic intervention remains. In this study,
two compounds were selected to determine the effects of
MMP inhibition on neuroinflammation and neural injury
after H-I. Minocycline, a tetracycline derivative known for
its anti-inflammatory properties, is neuroprotective in
several rat injury models [31-33] and has recently been
shown to inhibit MMP activity both in vitro and in vivo
[34]. AG3340, a small molecule hydroxamate-based
inhibitor of MMPs, is efficacious in limiting tumor growth
in rodent models [35,36] and was shown to be neuropro-
tective in adult rodents exposed to chronic ischemia [37].
While both compounds demonstrate good oral bioavaila-
bility, AG3340 is a potent MMP inhibitor with high
nanomolar affinity for gelatinases, specifically, when
compared to the broad anti-inflammatory actions of
minocycline. Results here show that both minocycline
and AG3340 reduced neuroinflammation and neural
injury when administered 24 hrs after H-I, highlighting
the potential of targeting MMPs when developing thera-
pies to combat neonatal H-I injury.
Methods
Induction of hypoxia-ischemia
All animal procedures were conducted in accordance with
the NIH Guide for the Care and Use of Laboratory Ani-
mals with a protocol approved by the Institutional Ani-
mal Care and Use Committee at the University of South
Florida. The number of animals used in this study was
limited to the fewest number to complete the project.
Neonatal Sprague-Dawley rats were birthed from time-
pregnant dams (Harlan Labs). Dams and litters were
maintained on a 12 hour light/dark cycle (7 am – 7 pm)
and given access to food and water ad libitum. Litters from
2 dams were culled to 10 pups per litter at postnatal day 1
(P1) and cross-fostered randomly between dams prior to
each experiment. Two H-I experiments consisting of ani-
mals from 2 litters per experiment were used in this study.
The H-I procedure was originally developed by Levine
[38] and reprised by Vannucci and colleagues [39,40] for
use in the neonate. The H-I methodology was described in
some detail previously [28]. Briefly, the procedure
entailed permanent unilateral ligation of the common
carotid artery followed by transient exposure to hypoxia.
P7 rats were anesthetized with 2.5% isofluorane, placed
on a heating pad (37°C) and maintained at 350 ml/min
of oxygen and 1.5% isofluorane with an interfaced scav-Journal of Neuroinflammation 2008, 5:34 http://www.jneuroinflammation.com/content/5/1/34
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enging system for the duration of the surgery. The right
common carotid artery was exposed, isolated away from
the vagus and ligated using a 6.0 nylon suture. The mus-
culature and skin were sutured, animals placed back with
their corresponding dams for a 2 h recovery period, and
subsequently exposed to 8% oxygen/N2 balanced for 90
min. During hypoxia, pups were placed into custom-
made chambers that maintained a temperature of 37°C
while permitting the water-saturated oxygen mixture to be
dispensed at a constant flow rate [27]. Pups were then
returned to their respective dams until initiation of the
treatment phase.
Drug treatment
Animals exposed to H-I were randomly assigned to receive
vehicle, minocycline (Sigma Aldrich, St. Louis, MO) or
AG3340 (AG3340 was kindly provided by Dr. Peter Baciu,
Allergan, Irvine, CA). Vehicle consisted of 50% DMSO +
25% propylene glycol in distilled water. Minocycline and
AG3340 were dissolved in vehicle to obtain stock solu-
tions of 13.5 mg/ml. Fresh stock solutions of drugs were
prepared every 2 days. Pups were weighed each day and
weight-based injection volumes were calculated to yield a
final dose of 45 mg/kg for each animal. Treatments were
administered once daily (s.c.) for 6 days beginning 24
hours after H-I (P8). Animals were evaluated daily for
signs of pain or discomfort, and no adverse effects were
observed in response to either compound or vehicle
alone. At the end of the treatment period, animals were
sacrificed for histochemical analyses.
Tissue preparation
For histochemical evaluation, tissues were collected 7
days after H-I (P14) as previously described [28]. Animals
were anesthetized with pentobarbital (60 mg/kg) and int-
racardially perfused with phosphate-buffered saline (PBS,
pH 7.4) followed by 4% paraformaldehyde. Brains were
removed and cryopreserved with increasing sucrose con-
centrations (15%, 30%), 30 μm thick sections were cut on
a cryostat, and the sections were thaw-mounted onto
Superfrost slides (Fisher Scientific, Suwane, GA). Direct
mounting onto slides achieved maximum preservation of
morphology of the tissue surrounding the lesion. Serial
sections were collected throughout the brain beginning at
approximately 1.2 mm rostral to bregma and ending at
approximately 5.8 mm caudal to bregma.
Histology and immunohistochemistry
Immunohistochemistry was performed as previously
described [28] to assess reactive astrogliosis and micro-
glia/macrophage recruitment to the injured site. Slides
were rinsed with PBS, permeabilized and blocked for 60
min (3% Triton-X, 3% 1 M Lysine, 10% NGS in PBS),
incubated overnight with primary antibody at 4°C,
washed three times with PBS, incubated for 60 min with
fluorescent-tagged secondary antibody at room tempera-
ture, and coverslipped using Vectashield aqueous mount-
ing media (Vector Labs, Burlingame, CA). Double-label
immunohistochemistry was achieved by co-incubation
with anti-mouse and anti-rabbit primary antibodies, and
subsequent co-incubation with secondary antibodies con-
jugated to distinct fluorophores for each respective species
of primary antibody.
Primary antibodies used in these studies were mouse anti-
glial fibrillary acidic protein (GFAP) (Roche Applied Sci-
ence, Indianapolis, IN; 1:1000) and mouse anti-OX-42
(Serotec, Raleigh, NC; 1:3000). Primary antibodies were
visualized using either Alexa Fluor 488 (green) or Alexa
Fluor 594 (red) secondary antibodies (Molecular Probes,
Eugene, OR). Working concentrations for secondary anti-
bodies were 1:300 for OX-42 and 1:1000 for all other pri-
mary antibodies.
In tissue sections from the central nervous system, Fluoro-
Jade stain mainly identifies areas of neural injury, pre-
dominantly degenerating neurons, and provides a posi-
tive quantitative marker as opposed to the absence of
signal when using Nissl stain. Fluoro-Jade was previously
shown to be a more sensitive measure of neural injury
when compared to triphenyltetrazolium chloride [41].
This method was adapted from Schmued and colleagues
[42] and subsequently detailed [41]. Tissues mounted on
glass slides were sequentially placed in 100% ethanol for
3 min, 70% ethanol for 1 min and deionized water for 1
min. Sections were oxidized for 15 min using 0.06%
KMnO4 solution followed by 3 brief rinses in PBS. Slides
were then immersed in a 0.001% solution of Fluoro-Jade
(Histochem, Jefferson, AR) in 0.1% acetic acid for 30 min,
rinsed with PBS, dried for 20 min at 45°C, cleared with
xylene and coverslipped using DPX medium (Electron
Microscopy Sciences, Ft. Washington, PA).
Image analyses and quantification
Images were acquired using a Zeiss Axioscope 2 (model
#801572) controlled by Openlab (Improvision Ltd, Lex-
ington, MA) software, and photomicrographs were cap-
tured with a Zeiss Axicam Color (model #412-312)
camera. All images subjected to direct comparisons were
captured at the same exposure and digital gain settings to
eliminate confounds of differential background intensity
or false-positive immunoreactivity across sections. Immu-
noreactivity was quantified using NIH ImageJ software.
Photomicrographs of sections from P14 rats were
imported into ImageJ and two distinct methods were
employed to best assess relative abundance of immunore-
activity. Histogram analyses were performed to assess
astrogliosis. Total GFAP intensity values were summed
based upon the frequency of positive pixels that occurred
within an intensity spectrum ranging from 0 (no immun-Journal of Neuroinflammation 2008, 5:34 http://www.jneuroinflammation.com/content/5/1/34
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ofluorescence detected) to 256 (highest immunofluores-
cence intensity). For GFAP quantification, 2 cortical fields
per section were selected for analyses. Cortical field selec-
tion was achieved by moving lateral from the most dorsal
aspect of the corpus callosum (layers 1–4), and again
moving medial-ventral to the adjacent field (layers 5–6).
For neural injury indicated by Fluoro-Jade stain, the entire
cortex was traced and background subtraction was
achieved by enhancing contrast until background parti-
cles were eliminated from the images. All sections were
selected at fixed intervals throughout the bregma coordi-
nates indicated in 'tissue preparation'.
Statistical analyses
Data from all treatment groups were expressed as X ± SEM.
For reactive astrogliosis and cell death, data were repre-
sented as total immunofluorescence intensity. Group
means were then subjected to a one-way ANOVA with "p
value" set at 0.05. Pair-wise comparisons of group means
were made using a Dunnett's Multiple Comparison test.
Results
Microglia/macrophage recruitment is associated with 
neural injury
Exposure of the neonate to H-I initiates injurious bio-
chemical cascades that facilitate recruitment of pro-
inflammatory cells to the lesion site. An early and sus-
tained indicator of CNS injury is the activation and
recruitment of microglia and macrophages to the injured
site. These cell types are important in the initiation and
maintenance of the neuroinflammatory response, includ-
ing the production of MMPs. Immunohistochemistry was
performed on sections from untreated and vehicle-treated
animals that were exposed to H-I (N = 5 per group) to
assess the immune cell response using anti-OX-42, an
antibody that binds the CD11b antigen that is expressed
on cell surfaces of microglia and macrophages. Intense
OX-42 immunoreactivity was detected 7 days after H-I
(Figure 1). Robust elevations in OX-42 – positive cells
occurred in the ipsilateral cerebral cortex (Figure 1B)
when compared to the contralateral control region (Figure
1A). Although some labeling was detected in the contral-
ateral cortex, immunoreactivity was faint and diffuse by
comparison. In contrast, cells expressing the CD11b anti-
gen were abundant throughout the striatum of both hem-
ispheres (Figure 1C,D). Closer examination revealed that
OX-42 – positive cells displayed an amoeboid morphol-
ogy in the ipsilateral striatum (Figure 1D) and cortex (Fig-
ure 1E) that is consistent with activated microglia or
macrophages, while CD11b – expressing cells in contral-
ateral striatum exhibited a ramified morphology.
Hypoxia-ischemia often produces cortical and subcortical
cavitary infarctions over time that are not present up to 4
days after insult. Tissues from vehicle-treated animals (N
= 5) were collected 7 days after H-I and stained with
Fluoro-Jade to determine the degree of neural injury
present at this time (Figure 2). Fluoro-Jade staining was
prominent in the ipsilateral hemisphere. Signal appeared
as columns in lower cortical layers and was diffusely dis-
tributed throughout the striatum (Figure 2A). The cortical
and striatal injury profile was consistent with elevated
OX-42 immunoreactivity (Figure 2C, Figure 1D). Fluoro-
Jade also stained hippocampal CA1–CA3 pyramidal neu-
rons intensely (Figure 2B), while other hippocampal
fields showed little staining. OX-42 immunoreactivity did
not colocalize with Fluoro-Jade in the pyramidal cell lay-
ers. However, CD11b – positive cells were localized to the
molecular layer of dentate gyrus and other regions seated
ventral to CA1 (Figure 2D). In general, Fluoro-Jade stain-
ing was present in and adjacent to regions that contained
increased numbers of activated microglia/macrophages,
indicating that the activation of these cells is associated
with neural injury.
Delayed treatment dampens reactive astrogliosis
Previous data demonstrated a robust astroglial response
early after H-I in the neonate, indicating that reactive
astrocytes are key players in neuroinflammation and
respond upstream of severe infarction [28]. To test
whether inhibition of MMPs can reduce astrocyte reactiv-
ity after H-I, immunohistochemistry was performed 7
days after H-I to assess GFAP upregulation (Figure 3) in
animals treated with vehicle, minocycline or AG3340 for
6 days after H-I. Low levels of GFAP were detected in con-
tralateral cerebral cortex (Figure 3A,G). In general, GFAP
immunoreactivity was prominent in ipsilateral somato-
sensory cortical layers 5–6 (Figure 3C,F,I) with lesser rela-
tive intensity in cortical layers 1–4 (Figure 3B,E,H).
Animals treated with vehicle alone showed robust
increases in GFAP in layers 1–4 (Figure 3B) and layers 5–
6 (Figure 3C). This is consistent with the astroglial
response previously reported at an earlier endpoint [28].
Astrogliosis was diminished after administration of either
minocycline or AG3340. While the observed effect of
minocycline was most evident in cortical layers 1–4 (Fig-
ure 3E), administration of AG3340 diminished astroglio-
sis in layers 1–4 (Figure 3H) and appeared more
efficacious in layers 5–6 (Figure 3I) when compared to
minocycline (Figure 3F). Quantification was performed
by analyzing photomicrographs (N = 8 per group, 5 sec-
tions per animal) for total GFAP immunoreactivity.
Results showed significant reductions in GFAP immuno-
reactivity in cortical layers 1–4 (Figure 3J) and layers 5–6
(Figure 3K) of animals treated with either minocycline or
AG3340 compared to treatment with vehicle alone (p <
0.05). Despite a clear trend toward diminished fluores-
cent signal in sections from animals treated with AG3340
relative to minocycline, efficacy did not differ significantly
between treatments.Journal of Neuroinflammation 2008, 5:34 http://www.jneuroinflammation.com/content/5/1/34
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Microglia/macrophages are activated and recruited to the lesion site 7 days after H-I Figure 1
Microglia/macrophages are activated and recruited to the lesion site 7 days after H-I. Exposure to H-I at P7 
resulted in increased CD11b – positive cells, as measured by OX-42 immunoreactivity, in ipsilateral somatosensory cortex (B) 
compared to contralateral control (A). CD11b – expressing cells were abundant in corpus striatum of both hemispheres but 
showed distinct morphology (C,D). Cells in the ipsilateral striatum displayed the activated amoeboid phenotype (D) similar to 
those in ipsilateral cortex (E) when compared to the ramified morphology in the contralateral hemisphere (C) that is associ-
ated with a less activated state. Scale bars = 100 μm (A,B), 50 μm (C-E).Journal of Neuroinflammation 2008, 5:34 http://www.jneuroinflammation.com/content/5/1/34
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Delayed treatment reduces neural injury
Marked increases in Fluoro-Jade staining were evident in
ipsilateral cerebral cortex, corpus striatum and hippocam-
pus of animals exposed to H-I and treated with vehicle
alone (Figure 2, 4). Staining was absent from the contral-
ateral hemisphere and very little non-specific background
staining was detected (Figure 4A,C,E). Intense columnar-
shaped immunofluorescence was evident throughout the
cerebral cortex in sections that ranged from the initial
emergence of lateral ventricles to ventral hippocampus.
Treatment with minocycline abolished this effect, show-
ing little or no cortical Fluoro-Jade labeling (Figure 4D).
Administration of AG3340 also reduced Fluoro-Jade
staining in cerebral cortex (Figure 4F) when compared to
sections from animals treated with vehicle alone, though
this compound appeared to be less efficacious than mino-
cycline. Quantification of cortical Fluoro-Jade staining
was performed by analyzing photomicrographs (N = 5 per
group, 5 sections per animal) for total area occupied by
stain. Results showed a significant reduction in Fluoro-
Jade staining after treatment with both compounds (Fig-
ure 4G) when compared to treatment with vehicle alone
(p < 0.05). Efficacy did not differ significantly between
minocycline and AG3340.
Microglia/macrophage activation and recruitment are associated with neural injury Figure 2
Microglia/macrophage activation and recruitment are associated with neural injury. Exposure to H-I at P7 resulted 
in robust Fluoro-Jade staining throughout cerebral cortex, corpus striatum (A) and CA1–CA3 pyramidal cell layers of hippoc-
ampus (B), indicating severe neural injury. OX-42 immunoreactivity showed CD11b – expressing cells at the cortical lesion site 
(C). Hippocampal OX-42 localized to the molecular layer of dentate gyrus and was evident in hippocampal regions seated ven-
tral to CA1, but was not present in the pyramidal cell layers (D). Scale bars = 100 μm.Journal of Neuroinflammation 2008, 5:34 http://www.jneuroinflammation.com/content/5/1/34
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Delayed treatment ameliorates microglia/macrophage 
response
To determine whether reduced cell death was associated
with microglia/macrophage recruitment to the lesion site,
immunohistochemistry was performed with anti-OX-42
to detect the CD11b antigen present on cell membranes of
microglia and macrophages. Tissues from animals treated
with vehicle alone showed increased OX-42 immunoreac-
tivity in the ipsilateral cerebral cortex (Figure 5B). CD11b
labeling in contralateral control regions was faint and dif-
fuse by comparison (Figure 5A), indicating that OX-42 –
positive cells were recruited to the injured area or that
those present markedly increased the expression of
CD11b. Treatment with minocycline ameliorated this
effect, as ipsilateral OX-42 immunoreactivity (Figure 5D)
was indistinguishable from that observed in the contralat-
eral control hemisphere (Figure 5C). OX-42 – positive
cells were also greatly reduced in ipsilateral cortex of ani-
mals treated with AG3340 (Figure 5F) relative to contral-
ateral control (Figure 5E).
Discussion
The central nervous system response to hypoxia-ischemia
or ischemia reperfusion injury often includes activation of
astrocytes, resident microglia, and the infiltration of
peripheral leukocytes. Subsequent release of pro-inflam-
matory cytokines and other inflammatory effectors con-
tribute to neural injury of white and gray matter after H-I
Delayed treatment with minocycline or AG3340 dampens reactive astrogliosis Figure 3
Delayed treatment with minocycline or AG3340 dampens reactive astrogliosis. P7 rat pups were exposed to H-I 
and treated with either vehicle, minocycline or AG3340 once daily for 6 days, beginning 24 hours after insult. (A-C) Astroglio-
sis, as measured by GFAP immunoreactivity, was markedly elevated in cortical layers 1–4 (B) and layers 5–6 (C) compared to 
contralateral control (A) after treatment with vehicle alone. Administration of either minocycline (D-F) or AG3340 (G-I) 24 
hours after H-I reduced GFAP immunoreactivity in layers 1–4 (E,H) and layers 5–6 (F,I) compared to control hemisphere 
(D,G). GFAP immunoreactivity was significantly reduced in cortical layers 1–4 (J) and layers 5–6 (K) of animals treated with 
either minocycline or AG3340 compared to treatment with vehicle alone. N = 8, * = p < 0.05. Scale bars = 100 μm.Journal of Neuroinflammation 2008, 5:34 http://www.jneuroinflammation.com/content/5/1/34
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[43]. The present study evaluated the degree of reactive
astrogliosis, microglia/macrophage recruitment and neu-
ral injury after H-I in the P7 Sprague-Dawley rat neonate.
A single daily administration of minocycline or AG3340
for 6 days, beginning 24 hrs after H-I, provided protection
against neural injury and dampened astrocyte and micro-
glial activation induced by the insult. Because of the pro-
gressive nature of the insult that follows H-I, it is likely
that inhibition of inflammatory effectors by minocycline
or AG3340 was associated with reduced neural injury.
The neurobiological reaction to H-I-induced lesion
involves a progressive inflammatory response that exacer-
bates the injury via the release of cytokines, chemokines
and other effector molecules from reactive astrocytes, res-
ident immune cells and peripheral leukocytes. Robust ele-
vations in GFAP immunoreactivity were prominent
throughout the ipsilateral cerebral cortex of animals
treated with vehicle alone. Fluoro-Jade histochemistry
revealed marked neural injury that was anatomically con-
sistent with heightened GFAP and OX-42 labeling. CD11b
– positive cells were abundantly distributed throughout
the cortex, striatum and hippocampus after insult. Evi-
dence indicates that resident microglia, and not infiltrat-
ing leukocytes, are the primary immune cells that respond
to ischemic injury in the neonatal rat brain [44]. Although
the majority of CD11b – expressing cells detected here
displayed an amoeboid morphology characteristic of acti-
vated microglia, it is also possible that these cells were
peripheral monocytes that had entered the brain after
insult.
MMPs, derived mainly from microglia, influence the neu-
rological outcome after hypoxia and/or ischemia-induced
lesion in a complex manner. After experimental stroke,
MMP-9 null mice showed reduced blood brain barrier
degradation and white matter injury [26]. However, more
recent data demonstrated that acute expression of MMPs
contributes to injury, yet more chronically, MMPs pro-
mote plasticity and recovery [45]. Most relevant, the
extent of neural injury induced by H-I in the rat neonate
was diminished in MMP-9 null mice compared to the
lesion in wild type mice [24]. MMP-9 co-localizes with
activated resident microglia [24] and infiltrating leuko-
cytes [25,46] in rodents subjected to cerebral ischemia,
indicating a link between activated immune cells and
MMP expression. Consistent with these data, the absence
of immune cell recruitment after treatment with inhibi-
tors in the present study provides further evidence that
MMP activity is linked to neuroinflammation.
Several different mechanisms could account for the neu-
roprotection afforded by AG3340. MMPs participate in
complex injury responses through interactions with and
activation of cytokines, chemokines and other pericellular
Delayed treatment with minocycline or AG3340 reduces  neural injury Figure 4
Delayed treatment with minocycline or AG3340 
reduces neural injury. P7 rat pups were exposed to H-I 
and treated with either vehicle, minocycline or AG3340 once 
daily for 6 days, beginning 24 hours after insult. Animals 
treated with vehicle alone showed robust Fluoro-Jade labe-
ling in ipsilateral cortex and corpus striatum (B). Fluoro-Jade 
staining was nearly abolished after treatment with minocy-
cline (D) and greatly reduced after treatment with AG3340 
(F) relative to vehicle alone (B). No labeling was detected in 
contralateral control regions (A,C,E). Quantification showed 
a significant reduction after treatment with either minocy-
cline or AG3340 (G) compared to treatment with vehicle 
alone. N = 5, * = p < 0.05. Scale bars = 100 μm.Journal of Neuroinflammation 2008, 5:34 http://www.jneuroinflammation.com/content/5/1/34
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Delayed treatment with minocycline or AG3340 ameliorates the microglia/macrophage response Figure 5
Delayed treatment with minocycline or AG3340 ameliorates the microglia/macrophage response. P7 rat pups 
were exposed to H-I and treated with either vehicle, minocycline or AG3340 once daily for 6 days, beginning 24 hours after 
insult. Intense OX-42 immunoreactivity was evident throughout the ipsilateral cerebral cortex of animals treated with vehicle 
alone (B). Microglia/macrophage labeling was nearly abolished after treatment with minocycline (D) and was markedly reduced 
after treatment with AG3340 (F). OX-42 immunoreactivity in contralateral control regions was faint and diffuse by comparison 
(A,C,E). Scale bars = 100 μm.Journal of Neuroinflammation 2008, 5:34 http://www.jneuroinflammation.com/content/5/1/34
Page 10 of 11
(page number not for citation purposes)
and cell surface substrates [47], and inhibition would
limit the action of these pro-inflammatory agents [16,45].
Because gelatinases efficiently degrade basement mem-
brane proteins, it is possible that the actions of the MMP
inhibitor resulted in preservation of basement membrane
proteins and an intact blood brain barrier. Another possi-
ble mechanism of the MMP inhibitor could be that a loss
of ECM proteolysis derived from microglia limited their
ability to migrate through the ECM to the region of injury
(or other unknown mechanisms). This is an interesting
potential mechanism which, to date, has not been inves-
tigated. Data from the present study indirectly support
such a mechanism since microglia/macrophage density in
the injured cerebral cortex was diminished in animals
treated with AG3340. Additionally, results here showed
that delayed administration of AG3340 24 h after H-I lim-
ited microglial numbers and conferred protection from
neural injury. This suggests that selective targeting of
MMPs even after an episode of H-I may be a clinically rel-
evant therapeutic approach.
Minocycline is known for its broad anti-inflammatory
actions and has recently been shown to inhibit MMP
activity in an in vivo stroke model [34]. In the present
study, we sought to determine the degree to which two
compounds that exhibit distinct anti-inflammatory
actions and affinities for MMPs, differentially influence
neural injury caused by H-I in the neonate. In a manner
similar to AG3340, minocycline reduced microglia/mac-
rophage recruitment and cortical injury after H-I. Both
compounds also inhibited astroglial reactivity in the
injured region, suggesting that MMPs may contribute to
the activation of astrocytes as well. Two other neonatal H-
I studies have demonstrated short-term [31] and long-
term [32] protection after treatment with minocycline.
Importantly, these experiments differed in that animals
were pretreated prior to insult and again immediately
after occlusion, whereas in the present study, treatment
did not begin until 24 hours after the insult.
Conclusion
The present study indicates that treatment with either
AG3340, a compound that is relatively selective for gela-
tin-degrading MMPs, or minocycline, a tetracycline deriv-
ative with anti-inflammatory and MMP-inhibitory
properties, protected the neonatal brain even when first
administered 24 h after H-I, a clinically relevant time
point. Future investigations are necessary to define the
early time course for efficacy, the specific pro-inflamma-
tory mechanisms involved in progressive H-I injury, and
the degree to which the neuroprotective effects of these
compounds are dependent on MMP activity. These stud-
ies, in conjunction with data reported here, will aid not
only in identifying the specific sequence of neuroinflam-
matory events that contribute to H-I injury, but also in
determining whether MMPs mediate these processes and
therefore represent attractive therapeutic targets.
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